

LISTĂ DE LUCRĂRI BUTUCĂ ANCA

A. Teza de doctorat:

„Studiul interacțiunilor excipienți - antihipertensive în cadrul formelor farmaceutice cu eliberare modificată”

Universitatea de Medicină și Farmacie „Iuliu Hațieganu” Cluj-Napoca, Domeniul Farmacie, Specializarea: Analiza medicamentelor

Coordonator: Prof. Dr. Marius Traian Bojiță

Data susținerii: 27.02.2015, confirmare prin Ordinul MECI Nr. 3869/19.05.2015

B. Cărți și capitole în cărți:

- *Autor unic*

Moisei Anca, „Analize fizico-chimice aplicate în preformularea unor combinații de antihipertensive” Ed. ULBS, Sibiu, 2015, 978-606-12-1198-2, **201** pag.

- *Co-autor:*

Arseniu Anca Maria, **Butucă Anca**, Cioca Gabriela, Dobrea Carmen Maximiliana, Frum Adina, Gligor Felicia Gabriela, Juncan Anca Maria, _Morgovan Claudiu, Muntean Andrei Cătălin, Rus Luca Liviu, Vonica Țincu Andreea Loredana, Felicia Gabriela Gligor (coord.) – „Farmacie – Teste grilă pentru examenul de licență”, Ed. ULBS, , 2022, 978-606-12-1930-8, 289 pag.

- *Capitole de cărți:*

Moisei Anca, Totan Maria, Mureșan Maria-Lucia, Rus Luca Liviu, „Chimie analitică și analiză instrumentală : Caiet de lucrări practice”, Ed. ULBS, Sibiu, 2015, 978-606-12-1197-5, pag.1-40

C. Articole ISI:

1. Buciuman, C.A.; Dobrea, C.M.; **Butuca, A.**; Frum, A.; Gligor, F.G.; Botea, M.O.; Vicaș, L.G.; Mureșan, M.E.; Gligor, O.; Maghiar, F.; et al. Pharmacovigilance Insights into Ibuprofen’s Neuropsychiatric Safety: A Retrospective Analysis of EudraVigilance Reports. *Pharmaceuticals* 2025, 18, 1301. <https://doi.org/10.3390/ph18091301>, **impact factor 4.8 (Q1)**

2. Buciuman, C.A.; Dobrea, C.M.; **Butuca, A.**; Frum, A.; Gligor, F.G.; Gligor, O.; Vicaș, L.G.; Morgovan, C. Exploring the Cardiovascular Safety Profile of Ibuprofen: Insights from EudraVigilance Database. *Pharmaceuticals* 2025, 18, 1045. <https://doi.org/10.3390/ph18071045>, **impact factor 4.8 (Q1)**
3. Popa Ilie, I.R.; **Butuca, A.**; Homorodean, C.; Dobrea, C.M.; Morgovan, C.; Frum, A.; Ghibu, S. Osilodrostat Safety Profile: Findings from Real-World Data in the FAERS Database. *J. Clin. Med.* 2025, 14, 3518. <https://doi.org/10.3390/jcm14103518>, **impact factor 2.9 (Q)**
4. **Butuca, A.**; Stoicescu, L.; Popa, M.L.; Dobrea, C.M.; Muntean, A.; Morgovan, C.; Pienar, C.; Gligor, F.G.; Ghibu, S.; Popa Ilie, I.R.; et al. Inefficiency Rates of Biological Immunosuppressive Induction Agents Used in Organ Transplantation: A Pharmacovigilance Study. *J. Clin. Med.* 2025, 14 (10), 3409. <https://doi.org/10.3390/jcm14103409>, **impact factor 2.9 (Q1)**
5. Vonica, R. C., **Butuca, A.**, Morgovan, C., Pumnea, M., Cipaian, R. C., Frum, A., Dobrea, C. M., Vonica-Tincu, A. L., Pacnejer, A.-M., Ghibu, S., Batar, F., & Gligor, F. G. (2025). Bevacizumab—Insights from EudraVigilance Database on the Assessments of the Safety Profile of Monoclonal Antibodies Used as Targeted Cancer Treatment. *Pharmaceuticals*, 18(4), 501. <https://doi.org/10.3390/ph18040501>, **impact factor 4.8 (Q1)**
6. Pacnejer, A.-M., Negru, M. C., Arseniu, A. M., Trandafirescu, C., Oancea, C., Gligor, F. G., Morgovan, C., **Butuca, A.**, & Dehelean, C. A. (2025). Comparative Analysis of Neuropsychiatric Adverse Reactions Associated with Remdesivir and Nirmatrelvir/Ritonavir in COVID-19 Treatment: Insights from EudraVigilance Data. *Journal of Clinical Medicine*, 14(6), 1886. <https://doi.org/10.3390/jcm14061886>, **impact factor 2,9 (Q1)**
7. Dobrea, C. M., Morgovan, C., Frum, A., **Butuca, A.**, Chis, A. A., Arseniu, A. M., Ghibu, S., Vonica, R. C., Gligor, F. G., Ilie, I. R. P., & Vonica Tincu, A. L. (2025). The Assessment of the Safety Profile of Selective Serotonin Reuptake Inhibitors Versus Other Antidepressants: Drug–Drug Interaction Insights from EudraVigilance. *Journal of Clinical Medicine*, 14(4), 1208. <https://doi.org/10.3390/jcm14041208>, **impact factor 2.9 (Q1)**
8. Vonica, R.C.; Morgovan, C.; **Butuca, A.**; Pumnea, M.; Cipaian, R.C.; Frum, A.; Dobrea, C.M.; Vonica-Tincu, A.L.; Pacnejer, A.-M.; Batar, F.; et al. Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug

Ineffectiveness from EudraVigilance Database. *Cancers* 2025, 17, 663. <https://doi.org/10.3390/cancers17040663>, **impact factor 4.4 (Q2)**

9. Muntean, C.; Solomon, A.; Cipaian, R.C.; Vonica, R.C.; **Butuca, A.**; Gaborean, V.; Faur, I.F.; Feier, C.V.I. The Efficacy and Safety of Anlotinib in the Treatment of Thyroid Cancer: A Systematic Review. *J. Clin. Med.* 2025, 14, 338. <https://doi.org/10.3390/jcm14020338>, **impact factor 2.9 (Q1)**

10. Pacnejer AM, **Butuca A**, Dobrea CM, Arseniu AM, Frum A, Gligor FG, Arseniu R, Vonica RC, Vonica-Tincu AL, Oancea C, Mogosan C. Neuropsychiatric Burden of SARS-CoV-2: A Review of Its Physiopathology, Underlying Mechanisms, and Management Strategies. *Viruses*. 2024 Nov 21;16(12):1811. <https://doi.org/10.3390/v16121811>, **impact factor 3,5 (Q2)**.

11. Popa Ilie, I.R.; Dobrea, C.M.; **Butuca, A.**; Homorodean, C.; Morgovan, C.; Vonica-Tincu, A.L.; Gligor, F.G.; Ghibu, S.; Frum, A. *Real-Life Data on the Safety of Pasireotide in Acromegaly: Insights from EudraVigilance*. *Pharmaceuticals* 2024, 17, 1631. <https://doi.org/10.3390/ph17121631> **impact factor: 4,8 (Q1)**

12. Vonica RC, **Butuca A**, Vonica-Tincu AL, Morgovan C, Pumnea M, Cipaian RC, Curca RO, Batar F, Vornicu V, Solomon A, Frum A. The Descriptive and Disproportionality Assessment of EudraVigilance Database Reports on Capecitabine Induced Cardiotoxicity. *Cancers*. 2024 Nov 16;16(22):3847. <https://doi.org/10.3390/cancers16223847>, **impact factor 4,4 (Q2)**,

13. Popa Ilie, I.R.; Vonica-Tincu, A.L.; Dobrea, C.M.; **Butuca, A.**; Frum, A.; Morgovan, C.; Gligor, F.G.; Ghibu, S. Safety Profiles Related to Dosing Errors of Rapid-Acting Insulin Analogs: A Comparative Analysis Using the EudraVigilance Database. *Biomedicines* 2024, 12, 2273. <https://doi.org/10.3390/biomedicines12102273>, **impact factor 3,9 (Q1)**

14. Dobrea CM, Frum A, **Butuca A**, Morgovan C, Stoicescu L, Chis AA, Arseniu AM, Rus LL, Gligor FG, Vonica-Tincu AL. *Drug–Drug Interactions of Selective Serotonin Reuptake Inhibitors: A Pharmacovigilance Study on Real-World Evidence from the EudraVigilance Database*. *Pharmaceuticals*. 2024 Sep 26;17(10):1278. doi: [10.3390/ph17101278](https://doi.org/10.3390/ph17101278), **impact factor 4,8 (Q1)**

15. Chis, A.A.; Dobrea, C.M.; Arseniu, A.M.; Frum, A.; Rus, L.-L.; Cormos, G.; Georgescu, C.; Morgovan, C.; **Butuca, A.**; Gligor, F.G.; et al. Antibody–Drug Conjugates—Evolution and Perspectives. *Int. J. Mol. Sci.* 2024, 25, 6969. <https://doi.org/10.3390/ijms25136969>, **impact factor 4.9 (Q1)**

16. **Butuca, A.**; Dobrea, C.M.; Arseniu, A.M.; Frum, A.; Chis, A.A.; Rus, L.L.; Ghibu, S.; Juncan, A.M.; Muntean, A.C.; Lazăr, A.E., Gligor F.G., Morgovan C., Vonica-Țincu L.A.; An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database. *Biomedicines* 2024, 12, 1124. <https://doi.org/10.3390/biomedicines12051124>, **impact factor 3,9 (Q1)**
17. Morgovan, C.; Dobrea, C.M.; **Butuca, A.**; Arseniu, A.M.; Frum, A.; Rus, L.L.; Chis, A.A.; Juncan, A.M.; Gligor, F.G.; Georgescu, C.; et al. Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance. *Biomedicines* 2024, 12, 953. <https://doi.org/10.3390/biomedicines12050953>, **impact factor 3,9 (Q1)**
18. Vintila, B.I.; Arseniu, A.M.; Morgovan, C.; **Butuca, A.**; Bîrluțiu, V.; Dobrea, C.M.; Rus, L.L.; Ghibu, S.; Bereanu, A.S.; Arseniu, R.; et al. A Real-World Study on the Clinical Characteristics, Outcomes, and Relationship between Antibiotic Exposure and *Clostridioides difficile* Infection. *Antibiotics* 2024, 13, 144. <https://doi.org/10.3390/antibiotics13020144>, **impact factor 4,6 (Q1)**.
19. Vintila, B.I.; Arseniu, A.M.; **Butuca, A.**; Sava, M.; Bîrluțiu, V.; Rus, L.L.; Axente, D.D.; Morgovan, C.; Gligor, F.G. Adverse Drug Reactions Relevant to Drug Resistance and Ineffectiveness Associated with Meropenem, Linezolid and Colistin: An Analysis Based on Spontaneous Reports from the European Pharmacovigilance Database. *Antibiotics* 2023, 12, 918. <https://doi.org/10.3390/antibiotics12050918>, **impact factor 4,8 (Q1)**
20. Vintila, B.I.; Arseniu, A.M.; Morgovan, C.; **Butuca, A.**; Sava, M.; Bîrluțiu, V.; Rus, L.L.; Ghibu, S.; Bereanu, A.S.; Roxana Codru, I.; et al. A Pharmacovigilance Study Regarding the Risk of Antibiotic-Associated *Clostridioides difficile* Infection Based on Reports from the EudraVigilance Database: Analysis of Some of the Most Used Antibiotics in Intensive Care Units. *Pharmaceuticals* 2023, 16, 1585. <https://doi.org/10.3390/ph16111585>, **impact factor: 4,6 (Q1)**
21. Pop, G.; Farcaș, A.; **Butuca, A.**; Morgovan, C.; Arseniu, A.M.; Pumnea, M.; Teodoru, M.; Gligor, F.G. Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance. *Pharmaceuticals* 2022, 15, 1536. <https://doi.org/10.3390/ph15121536>, **impact factor 4,6 (Q1)**
22. Chis, A.A.; Arseniu, A.M.; Morgovan, C.; Dobrea, C.M.; Frum, A.; Juncan, A.M.; **Butuca, A.**; Ghibu, S.; Gligor, F.G.; Rus, L.L. Biopolymeric Prodrug Systems as

Potential Antineoplastic Therapy. *Pharmaceutics* 2022, 14, 1773, , <https://doi.org/10.3390/pharmaceutics14091773>, **impact factor 6.5 (Q1)**

23. Frum, A.; Dobrea, C.M.M.; Rus, L.L.; Virchea, L.-I.I.; Morgovan, C.; Chis, A.A.A.; Arseniu, A.M.M.; **Butuca, A.**; Gligor, F.G.G.; Vicas, L.G.G.; Tita, O.; Georgescu, C. Valorization of Grape Pomace and Berries as a New and Sustainable Dietary Supplement: Development, Characterization, and Antioxidant Activity Testing. *Nutrients* 2022, 14, 3065. <https://doi.org/10.3390/nu14153065>, **impact factor 6.7 (Q1)**

24. Rus, L.L.; Juncan, A.M.; Crăciun, V.I.; Frum, A.; Hegheș, S.-C.; **Butuca, A.**; Dobrea, C.M.; Chis, A.A.; Muntean, A.C.; Vonica-Țincu, A.L.; Morgovan, C. Determination of Zn²⁺ in Solid Pharmaceutical Dosage Forms by Means of Spectrophotometry in Micellar Media: Method Validation. *Appl. Sci.* 2022, 12, 4476, <https://doi.org/10.3390/app12094476>, **impact factor 2,7 (Q2)**

25. Chis, A.A.; Dobrea, C.M.; Rus, L.-L.; Frum, A.; Morgovan, C.; **Butuca, A.**; Totan, M.; Juncan, A.M.; Gligor, F.G.; Arseniu, A.M. Dendrimers as Non-Viral Vectors in Gene-Directed Enzyme Prodrug Therapy. *Molecules* 2021, 26, 5976, <https://doi.org/10.3390/molecules26195976>, **impact factor 4,927 (Q2)**

26. Chis, A.A.; Dobrea, C.; Morgovan, C.; Arseniu, A.M.; Rus, L.L.; **Butuca, A.**; Juncan, A.M.; Totan, M.; Vonica-Tincu, A.L.; Cormos, G.; Muntean, A.C.; Muresan, M.L.; Gligor, F.G.; Frum, A. Applications and Limitations of Dendrimers in Biomedicine. *Molecules* 2020, 25, 3982.. doi.org/10.3390/molecules25173982, **impact factor 4,412 (Q2)**

27. Morgovan, C.; Cosma, S.A.; Valeanu, M.; Juncan, A.M.; Rus, L.L.; Gligor, F.G.; **Butuca, A.**; Tit, D.M.; Bungau, S.; Ghibu, S. An Exploratory Research of 18 Years on the Economic Burden of Diabetes for the Romanian National Health Insurance System. *Int. J. Environ. Res. Public Health* 2020, 17, 4456, [doi: 10.3390/ijerph17124456](https://doi.org/10.3390/ijerph17124456), **impact factor 3,390 (Q1)**

28. Andrei Catalin Muntean, Anca Maria Juncan, Dana Georgiana Moisa, Andreea Loredana Vonica, Luca Liviu Rus, Claudiu Morgovan, Felicia Gabriela Gligor , **Anca Butuca** , Adriana Stanila, Primary Packaging and Stability Evaluation of a Serum Used for the Periorbital Area of the Sensitive Eye, *Materiale plastice*, 2019, 56(2): 360-365, impact factor: 1,517, (Q4),

29. Claudiu Morgovan, Steliana Ghibu, Anca Maria Juncan, Luca Liviu Rus, **Anca Butuca**, Loredana Vonica, Andrei Muntean, Liana Moș, Felicia Gligor, Neli-Kinga

Olah, Nutrivigilance: a new activity in the field of dietary supplements, Farmacia, 2019, 67(3): 537-544, **impact factor 1,607**

30. Juncan Anca Maria, **Butucă Anca**, Rus Luca Liviu, Morgovan Alexe-Claudiu, Innovations in the Use of Emollients in Cosmetic Products for Skin Care, Proceedings of The Romanian National Congress Of Pharmacy – 17th Edition “21st Century Pharmacy – Between Intelligent Specialization And Social Responsibility”, București, 26-29.09.2018, 107-112, ISBN 978-88-85813-28-1, ISI PROCEEDING

31. **Moisei A**; Totan M ; Gligor FG; Craciun I; Todoran N; Chis AA; Popa DE, *The Simultaneous Determination Of Candesartan, Amlodipine And Hydrochlorothiazide By High-Performance Liquid Chromatography, From A Mixture And Pharmaceutical Formulations*. Farmacia 2016, 64(4), 612-618, **impact factor: 1,348**

32. **Moisei A.**, Gligor F., Bojiță, M., Chiș A., Totan M., Vonica-Gligor L. A., & Ciurba. A. Compatibility and stability studies of antihypertensive/excipients by thermal methods, used in the preformulation phase. Farmacia 2014, 62(6), 1239-124, **impact factor: 1,005**

33. Ciurba, A., Todoran, N., Tăurean, A., Antonoaea, P., Hancu, G., **Moisei, A.**, & Sipos, E. Kinetic analysis of in vitro drug release from valproic acid and sodium valproate suppositories. Farmacia 2014, 62(6), 1143-1156, **impact factor: 1,005**

D. Articole BDI

1. Andrei – Cătălin Muntean, Cristina-Ioana Roth, Felicia Gabriela Gligor, Claudiu Morgovan, Anca Maria Juncan, **Anca Butucă**, Oana Iuliana Negoii, Adriana Stănilă, *Management of dry eye disease In pharmacies from Sibiu County*, Acta Medica Transilvanica, 2019, 24(2): 27-30, BDI

2. Bogdan Ioan Vintilă, **Anca Butucă**, Claudiu Morgovan, Andreea Loredana Vonica, Luca Liviu Rus, Andrei Cătălin Muntean, Anca Maria Juncan, Felicia Gabriela Gligor, Adverse effects of gonadotropins used in infertility treatment, International Conference on Innovations in Science and Education, 846-852; March 20-22 2019, Prague, Czech Republic, <https://ojs.journals.cz/index.php/CBUIC/article/view/1465/1990> (ISI Proceeding)

3. Andrei – Cătălin Muntean, Cristina-Ioana Roth, Felicia Gabriela Gligor, Claudiu Morgovan, Anca Maria Juncan, **Anca Butucă**, Oana Iuliana Negoii, Adriana Stănilă,

Management of dry eye disease In pharmacies from Sibiu County, Acta Medica Transilvanica, 2019, 24(2): 27-30, BDI

4. **Moisei A.**, Bojiță M., Chiș A., Totan M., Gligor F. – Thermal analysis study of the compatibility between antihypertensives and excipients, Current Health Science Journal (supp 8), 2014, 40, 28-31 BDI

5. Totan M., Gligor F., Bojiță M., Grigore C., Marchian S., **Moisei A.** – Importanța clinica a determinării feritinei serice. Stabilirea valorilor de referință, Acta Medica Transilvanica, 2013, 4 (vol. 2), 114-116 BDI

6. Cosmina Muntean, **Anca Moisei**, " Clinical Assessment of depressive disorder and comorbid viral hepatitis", Current Health Science Journal, 2013, 39(14),44-52. BDI

7. Cosmina Muntean, **Anca Moisei**, Ioan Andronic," Cognitive impairment in the course of depressive disorder associated with chronic hepatitis ", Roumanian Journal of Psychopharmacology, 2013,13(2),101-108. BDI

E. Lucrări ISI publicate în rezumat:

1. A. Frum, D. G. Moisă, A. M. Juncan, L. L. Rus, C. M. Dobrea, A. M. Arseniu, A. A. Chiș, **A. Butuca**, F. G. Gligor, C. Morgovan, Thrombosis and death: serious coincidental events after COVID-19 vaccination, Naunyn-Schmiedeberg's Arch Pharmacol, (2022) 395 (Suppl 1): 279, DOI 10.1007/s00210-022-02205-7

2. C. Morgovan, A. Juncan, L.L. Rus., A. A. Chiș, A. Frum, C. Dobrea, **A. Butucă**, A. Arseniu, L. Vonica, F. Gligor, S. Ghibu, COVID-19 Vaccination Program in Romania: an overview on implementation and monitoring of adverse reactions, NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 394(SUPPL 1), S35-S35

3. Claudiu Morgovan, **Anca Butucă**, Anca Maria Juncan, Luca Liviu Rus, Andrei Cătălin Muntean, Loredana Andreea Vonica, Adina Frum, Carmen Maximiliana Dobrea, Felicia Gabriela Gligor, Steliana Ghibu, An overview of dapgliflozin serious adverse reactions caused by potential interactions, 5th German PharmaTox Summit, 2-5 March 2020, Leipzig, Germany, Naunyn-Schmiedeberg'sArchPharmacol, 2020, 393, suppl 1, SI, 42-42, WOS 000514970800154.

4. **Anca Butucă**, Adina Frum, Felicia Gabriea Gligor, Anca Maria Juncan, Andrei Cătălin Muntean, Luca Liviu Rus, Carmen Maximilian Dobrea, Adriana Aurelia Chiș, Claudiu Morgovan, Interferon's adverse reactions, an impediment in the adherence to treatment, 5th German PharmaTox Summit, 2-5 March 2020, Leipzig, Germany,

Naunyn-Schmiedeberg'sArchPharmacol, 2020, 393, suppl 1, SI, 43-43, WOS 000514970800157

5. Anca Maria Arseniu, **Anca Butucă**, Maria Totan, Gabriela Cormoș, Claudiu Morgovan, Andrei Cătălin Muntean, Maria Mureșan, Adriana Aurelia Chiș, Prevalence of fatal adverse drug reactions reported for single enantiomer esomeprazole compared to racemic drug omeprazole, 5th German PharmaTox Summit, 2-5 March 2020, Leipzig, Germany, Naunyn-Schmiedeberg'sArchPharmacol, 2020, 393, suppl 1, SI, 43-43, WOS: 000514970800160.

6. Morgovan C., Valeanu B., **Butuca A.**, Rus L.L., Arseniu A., Gligor F., Dobrea C., Cardiac Toxicity of Trastuzumab in Non-metastatic breast cancer HER2-positive – The experience of County Oncology Clinic Sibiu, Romania, 19th Annual Meeting of the International-Society-of-Pharmacovigilance (ISoP) - New Opportunities for New Generations Bogota Columbia / Drug Safety **IF = 3,643, Q1 (abstract)**, ISSN: 0114-5916, 2019, 41(10): 1266-1267, WOS:000485893700120

7. **Butuca, A.**; Rus, L.; Morgovan C.; Lupse, I.; Juncan, A.; Vonica-Tincu, L.; Gligor, F.; Muntean, A.; Ghibu, S. How the Romanian Women Perceive the Advantages and Risks of the Contraceptives?, 19th Annual Meeting of the International-Society-of-Pharmacovigilance (ISoP) - New Opportunities for New Generations Bogota Columbia / Drug Safety **IF = 3,643, Q1 (abstract)**, ISSN: 0114-5916, 2019, 42(10), 1282-1282, WOS:000485893700042.

8. Morgovan C., Juncan A.M., **Butuca A.**, Rus L.L., Vonica L., Muntean A., Gligor F., Ghibu S., A new activity for safety use of dietary supplements, 21st Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT), Stuttgart Germany, Naunyn-Schmiedeberg'sArchPharmacol, 2019, (Suppl1): 392 S58, DOI 10.1007/s00210-01-0121- (201)39 **IF- 2,238, Q3** (abstract)

9. **Butuca, A.** Morgovan C., Juncan, A., Vonica L., Muntean A., Gligor F., *A Study Regarding the Frequency of Adverse Reactions in the Infertility Treatment*, 18th ISoP Annual Meeting on Pharmacovigilance without Borders, Geneva, SWITZERLAND, Drug Safety, 2018, 41(11): 1215-1216, ISoP-132 – **IF = 3,643, Q1** (abstract)